Efficacy and other milestones for human papillomavirus vaccine introduction.
about
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursorsProphylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursorsThe role of HPV in head and neck cancer and review of the HPV vaccinePrevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, IndiaCurrent global status & impact of human papillomavirus vaccination: Implications for IndiaPopulation-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysisHuman Papillomavirus Infection, Infertility, and Assisted Reproductive OutcomesThe potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.Potential anti-HPV and related cancer agents from marine resources: an overview.Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trialSocial values and scientific evidence: the case of the HPV vaccines.Predicting pediatricians' communication with parents about the human papillomavirus (hpv) vaccine: an application of the theory of reasoned action.Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study)Asia oceania guidelines for the implementation of programs for cervical cancer prevention and control.Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex tProduction of human papilloma virus type 16 e6 oncoprotein as a recombinant protein in eukaryotic cells.Next Generation Cancer Protection: The Bivalent HPV Vaccine for FemalesHuman papillomavirus vaccines launch a new era in cervical cancer prevention.Prophylactic HPV vaccines.Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids; a Strategy for Non-replicating Vaccines.A review of clinical trials of human papillomavirus prophylactic vaccines.High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upPreventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical CancersTranslational mini-review series on vaccines: Monitoring of human papillomavirus vaccination.The human papillomavirus vaccine: The promise of cervical cancer preventionExploring the relation between human papilloma virus and larynx cancer.HPV vaccination programs have not been shown to be cost-effective in countries with comprehensive Pap screening and surgery.Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical diseaseKnowledge of HPV among United States Hispanic women: opportunities and challenges for cancer prevention.Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs.How to evaluate emerging technologies in cervical cancer screening?Vaccines and biosimilarity: a solution or a problem?Globalization and perinatal medicine--how do we respond?Cost–effectiveness of catch-up programs in human papillomavirus vaccination.Monitoring of human papillomavirus vaccination.Economic evaluation of human papilloma virus vaccination in the European Union: a critical review.Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer.Factors impacting HPV vaccination: lessons for health care professionals.Human papillomavirus infection and intrauterine growth restriction: A data-linkage study.
P2860
Q24202048-A58EBBFF-A7BB-4234-9460-856F3D147268Q24235373-1656D8D5-611B-40B1-A0D5-5A4D0A3D392BQ24630128-5877A144-83A6-4217-AE69-0370E1264FD7Q25257293-2BE7080B-5BCE-4A53-866A-840AEC6F813BQ28079776-C775B32F-CD07-4257-AD58-32DC8A7D8084Q28084924-7AE5B218-73F4-4EB6-AD54-C5F5851AE58FQ28088327-E0DF0696-F359-4E2D-BD55-125EF6138EC1Q30251408-2AF4AD4B-7CA0-41EC-8B96-52F01FD6454DQ33292779-754A0E7E-3D9D-4CF0-BD93-E45714F358CBQ33575647-53EB65BB-E767-4A83-9647-79BEBDBF1815Q33626255-FE2FB8F0-A4E5-40F9-88A4-B77D248CCF64Q33890189-10EC4B85-CFA6-4C63-8A79-70175A0E6EF5Q34130796-7350E46F-7968-4C59-8CE2-2ADAA7F2480CQ34777452-1D7662D6-4500-4258-890B-125F97476ED2Q34866621-86F49E9C-7359-4F04-AB6D-5791676100E7Q35021139-0F5DABB4-254A-4461-AB06-6E9035C0CC2DQ35156193-ACE9F055-8FFE-4D32-A768-32A78563EEF5Q35550810-9A648A7A-F3F4-4FBC-8548-F09C9DE58886Q35944623-63188CA1-9FA2-48AE-A6AD-DD508454991BQ35984558-89F27A9A-8E04-40D4-B6C6-BBB95F1842B3Q36254152-2BAE02E9-FFDA-4394-B4A7-EC7275DC8C80Q36259403-40637B41-61E3-4B61-9EBE-935C45AEC20EQ36612475-42245B91-0AF4-467E-BBF3-9ADB7D35A3F3Q36652548-C4BCA81F-3C93-469A-AE0F-3D95FCE475D0Q36793117-9BCA52D8-E5EC-4AAF-A021-E70EEBCD362FQ36871265-AA7FC7EB-5921-4B4E-8630-4178AFDC7388Q36916029-42BD09D8-F1AE-4B12-B3D8-C32C7FD3808EQ36972495-58F94DEF-AEC0-4147-91FE-5C8C6001B432Q37134986-FA131310-64DB-4DC6-9593-374E54AF934CQ37382421-BA5C6C67-6BA1-446F-BE15-8A2188767A86Q37467138-A5865EF1-95F6-4305-8C82-45970C8FE114Q37467429-1FFEF64C-D7CD-45C1-8256-3E192142E84CQ37608322-635E634B-0CFC-4B38-AE68-9D60D5BC1217Q37628746-3797C1FD-2D28-4E44-8BB7-CFA7A1ACA05CQ37798010-889FECE3-02E9-4219-A385-5C6CD0C3F365Q37808256-487D15B9-0C9F-4815-88D0-D76F975E4B68Q37839828-D32FE285-12EF-4379-8590-9BA296DB04EBQ38182714-EC336B67-923E-40A1-BE95-2ECC8D53961FQ38223242-02AC7868-3F58-4469-8DEE-C11709FC3DD2Q40049003-244EFC5F-12F6-4E41-8C64-3CC412F03A04
P2860
Efficacy and other milestones for human papillomavirus vaccine introduction.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Efficacy and other milestones for human papillomavirus vaccine introduction.
@ast
Efficacy and other milestones for human papillomavirus vaccine introduction.
@en
type
label
Efficacy and other milestones for human papillomavirus vaccine introduction.
@ast
Efficacy and other milestones for human papillomavirus vaccine introduction.
@en
prefLabel
Efficacy and other milestones for human papillomavirus vaccine introduction.
@ast
Efficacy and other milestones for human papillomavirus vaccine introduction.
@en
P1433
P1476
Efficacy and other milestones for human papillomavirus vaccine introduction.
@en
P2093
M Teresa Aguado
Sonia R Pagliusi
P304
P356
10.1016/J.VACCINE.2004.07.046
P407
P577
2004-12-01T00:00:00Z